Meanwhile, the phase 2 study-NEJ005 reported that patients with the EGFR mutant NSCLC could benefit from combined chemotherapy and TKIs with a longer OS compared with TKIs alone (median, 41.9 vs. 30.7 months, p = 0.036) [16]. Here, EGFR is linked to non-small cell lung carcinoma.